Stock Price & Analysis

Based on the analysis of Moderna's stock performance, insider activity, and market trends, it is currently a hold for most investors. The stock shows potential for long-term growth due to its pipeline and recent insider buying, but short-term volatility and mixed analyst sentiment suggest caution.

Price Prediction for MRNA Stock in 2025

Based on current trends and analysis, Moderna (MRNA) stock is expected to trade in the range of $30 to $50 in 2025.

1. Bullish Scenario: The stock could reach $50 driven by CEO Stephane Bancel's recent share purchase and potential new product approvals.
2. Bearish Scenario: It may drop to $30 due to declining COVID vaccine demand and legal challenges.

Reason: MRNA's price is influenced by its pipeline progress and market sentiment shifts.

The S1 support level for MRNA Stock is $30.45 ,The R1 resistant level for MRNA Stock is $37.15.

As of the end of day on 2025-03-14, the price of MRNA Stock was $34.59.

The target price for MRNA Stock according to analyst rating is 42.73, with the highest price target at 78.00 and the lowest at 25.00. Analysts have a Hold rating on MRNA Stock overall.

The market cap of MRNA is $13.4B.

Moderna (MRNA) may be undervalued based on its strong financials and growth prospects. The stock closed at $35.96 on March 10, 2025, with a high trading volume of 12,537,670, indicating market interest. Its RSI of 53.90 suggests it's not overbought, and the MACD is slightly bearish at -0.64. Insider buying, including CEO Stephane Bancel's $5M purchase, signals confidence. With a high Value Investor score of 86%, MRNA appears undervalued, but risks like legal disputes and revenue diversification remain.

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.

Moderna Inc. (MRNA) is expected to reach a stock price of $200 by 2030, driven by strong fundamentals, positive insider activity, and favorable analyst sentiment. The stock's current trends, including CEO Stephane Bancel's recent share purchase and a high Value Investor rating, support this bullish outlook.

MRNA has a total of 5600 employees.